A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

Completed · Phase 2

Conditions studied: Asperger's Disorder, Pervasive Developmental Disorder

In brief

The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for reducing aggression and repetitive behavior.

Key facts

Study ID

NCT00198055

Run by

Indiana University

People needed

25

Starts

2005-01-01

Expected to finish

2007-09-01

Last updated by the study team

2014-06-04

Who can join

Age: 4 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mental age of 18 months
• Diagnosis of Asperger's Disorder or Pervasive Developmental Disorder
• Good health overall
• Free of all psychotropic medication for 2 weeks

You may not qualify if…

• Weight less than 15kg
• Subjects who have received an adequate trial of aripiprazole
• An active seizure disorder
• A significant medical condition
• History of neuroleptic malignant syndrome
• Females with positive Beta human chorionic gonadotropin(HCG) pregnancy test

Where it is running

• Riley Hospital, Riley Child and Adolescent Psychiatry Clinic — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.